DK2421537T3 - Pyrazolylaminopyridiner som inhibitorer af FAK - Google Patents

Pyrazolylaminopyridiner som inhibitorer af FAK

Info

Publication number: DK2421537T3
Authority: DK; Denmark
Prior art keywords: pyrazolylaminopyridines; fak; inhibitors
Prior art date: 2008-10-27

Application number

DK09829580.1T

Other languages

English (en)

Inventor

Jerry Leroy Adams

Thomas H Faitg

Neil W Johnson

Hong Lin

Jiri Kasparec

Mark Mellinger

Ren Xie

Xin Peng

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-27

Filing date

2009-10-27

Publication date

2015-06-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42132177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2421537(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-10-27 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2015-06-22 Application granted granted Critical

2015-06-22 Publication of DK2421537T3 publication Critical patent/DK2421537T3/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Pathology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK09829580.1T 2008-10-27 2009-10-27 Pyrazolylaminopyridiner som inhibitorer af FAK DK2421537T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US10856808P	2008-10-27	2008-10-27
US17851709P	2009-05-15	2009-05-15
US24243209P	2009-09-15	2009-09-15
PCT/US2009/062163 WO2010062578A1 (en)	2008-10-27	2009-10-27	Pyrazolylaminopyridines as inhibitors of fak

Publications (1)

Publication Number	Publication Date
DK2421537T3 true DK2421537T3 (da)	2015-06-22

Family

ID=42132177

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK09829580.1T DK2421537T3 (da)	2008-10-27	2009-10-27	Pyrazolylaminopyridiner som inhibitorer af FAK

Country Status (35)

Country	Link
US (6)	US20110207743A1 (da)
EP (1)	EP2421537B1 (da)
JP (1)	JP5642689B2 (da)
KR (1)	KR101512217B1 (da)
CN (1)	CN102264371B (da)
AR (1)	AR073993A1 (da)
AU (1)	AU2009320144B2 (da)
BR (1)	BRPI0920053B8 (da)
CA (1)	CA2741760C (da)
CL (1)	CL2011000933A1 (da)
CO (1)	CO6361929A2 (da)
CR (1)	CR20110264A (da)
CY (1)	CY1116399T1 (da)
DK (1)	DK2421537T3 (da)
DO (1)	DOP2011000113A (da)
EA (1)	EA021927B1 (da)
ES (1)	ES2539835T3 (da)
HR (1)	HRP20150531T1 (da)
IL (1)	IL212444A (da)
JO (1)	JO3067B1 (da)
MA (1)	MA32727B1 (da)
MX (1)	MX2011004369A (da)
MY (1)	MY161890A (da)
NZ (1)	NZ592477A (da)
PE (1)	PE20110941A1 (da)
PL (1)	PL2421537T3 (da)
PT (1)	PT2421537E (da)
RS (1)	RS54045B1 (da)
SG (1)	SG195608A1 (da)
SI (1)	SI2421537T1 (da)
SM (1)	SMT201500157B (da)
TW (1)	TWI454467B (da)
UY (1)	UY32200A (da)
WO (1)	WO2010062578A1 (da)
ZA (1)	ZA201102892B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8338441B2 (en)	2009-05-15	2012-12-25	Gilead Sciences, Inc.	Inhibitors of human immunodeficiency virus replication
US20120244141A1 (en)	2010-09-28	2012-09-27	Boehringer Ingelheim International Gmbh	Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
MX2013008654A (es) *	2011-01-26	2013-09-02	Glaxosmithkline Intellectual Property Ltd	Combinaciones.
JP5937112B2 (ja)	2011-02-17	2016-06-22	カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒＴｈｅｒａｐｅｕｔｉｃｓＣｒｃＰｔｙＬｉｍｉｔｅｄ	選択的ｆａｋ阻害剤
EP2675793B1 (en)	2011-02-17	2018-08-08	Cancer Therapeutics Crc Pty Limited	Fak inhibitors
RU2014102595A (ru)	2011-06-28	2015-08-20	Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед	Способ введения и лечения
US10106834B2 (en)	2013-10-09	2018-10-23	The General Hospital Corporation	Methods of diagnosing and treating B cell acute lymphoblastic leukemia
JP2018519327A (ja)	2015-06-29	2018-07-19	ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ．	治療用組成物、組合せ物および使用の方法
CN108948019B (zh) *	2017-05-18	2022-07-08	广东东阳光药业有限公司	黏着斑激酶抑制剂及其用途
WO2019117813A1 (en) *	2017-12-15	2019-06-20	National University Of Singapore	Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
JP2021517589A (ja)	2018-03-12	2021-07-26	アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル）	癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用
CN108912095B (zh) *	2018-08-09	2019-08-20	广州安岩仁医药科技有限公司	苯并咪唑类化合物及其制备方法和应用
AU2019348011A1 (en) *	2018-09-27	2021-02-11	Dana-Farber Cancer Institute, Inc.	Degradation of FAK or FAK and ALK by conjugation of FAK and ALK inhibitors with E3 ligase ligands and methods of use
WO2020135442A1 (zh) *	2018-12-27	2020-07-02	成都海创药业有限公司	一种fak抑制剂及其联合用药物
EP3937943A4 (en)	2019-03-15	2022-12-07	The General Hospital Corporation	NEW SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS
CN113387947B (zh) *	2021-07-12	2022-07-01	中国科学院成都生物研究所	调节雌激素受体合成活性的吡唑并吡啶衍生物
AU2024265078A1 (en)	2023-05-04	2025-12-11	Revolution Medicines, Inc.	Combination therapy for a ras related disease or disorder
IL326136A (en)	2023-08-07	2026-03-01	Revolution Medicines Inc	RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en)	2023-10-12	2025-05-15	Revolution Medicines, Inc.	Ras inhibitors
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
WO2025240847A1 (en)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Ras inhibitors
US20250375445A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en)	2024-08-29	2026-03-05	Revolution Medicines, Inc.	Ras inhibitors
WO2026072904A2 (en)	2024-09-26	2026-04-02	Revolution Medicines, Inc.	Compositions and methods for treating lung cancer
CN119499253A (zh) *	2024-11-15	2025-02-25	贵州医科大学	一种化合物在抑制Aurora和JAK激酶家族活性及在几种肿瘤治疗方面的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US166139A (en) *		1875-07-27		Improvement in dental pluggers
US6316603B1 (en) *	1998-09-08	2001-11-13	Agouron Pharmaceuticals, Inc.	Modifications of the VEGF receptor-2 protein and methods of use
US7102009B2 (en)	2001-01-12	2006-09-05	Amgen Inc.	Substituted amine derivatives and methods of use
NZ585188A (en) *	2003-08-15	2011-09-30	Novartis Ag	2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0419160D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
GB0419161D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
EP1746096A1 (en) *	2005-07-15	2007-01-24	4Sc Ag	2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
DK2134689T3 (da) *	2007-03-16	2014-06-30	Scripps Research Inst	Inhibitorer af fokal adhæsionskinase
WO2009105498A1 (en) *	2008-02-19	2009-08-27	Smithkline Beecham Corporation	Anilinopyridines as inhibitors of fak
MX2010014057A (es) *	2008-06-17	2011-03-21	Astrazeneca Ab	Compuestos de piridina.

2009
- 2009-10-25 JO JOP/2009/0395A patent/JO3067B1/ar active
- 2009-10-26 UY UY32200A patent/UY32200A/es not_active Application Discontinuation
- 2009-10-26 TW TW98136145A patent/TWI454467B/zh not_active IP Right Cessation
- 2009-10-27 EP EP20090829580 patent/EP2421537B1/en active Active
- 2009-10-27 CA CA2741760A patent/CA2741760C/en active Active
- 2009-10-27 BR BRPI0920053A patent/BRPI0920053B8/pt active IP Right Grant
- 2009-10-27 PE PE2011000920A patent/PE20110941A1/es not_active Application Discontinuation
- 2009-10-27 WO PCT/US2009/062163 patent/WO2010062578A1/en not_active Ceased
- 2009-10-27 NZ NZ59247709A patent/NZ592477A/xx not_active IP Right Cessation
- 2009-10-27 DK DK09829580.1T patent/DK2421537T3/da active
- 2009-10-27 KR KR1020117011999A patent/KR101512217B1/ko not_active Expired - Fee Related
- 2009-10-27 RS RS20150365A patent/RS54045B1/sr unknown
- 2009-10-27 AU AU2009320144A patent/AU2009320144B2/en not_active Ceased
- 2009-10-27 US US13/126,064 patent/US20110207743A1/en not_active Abandoned
- 2009-10-27 PL PL09829580T patent/PL2421537T3/pl unknown
- 2009-10-27 PT PT98295801T patent/PT2421537E/pt unknown
- 2009-10-27 AR ARP090104137 patent/AR073993A1/es not_active Application Discontinuation
- 2009-10-27 MX MX2011004369A patent/MX2011004369A/es active IP Right Grant
- 2009-10-27 JP JP2011533421A patent/JP5642689B2/ja active Active
- 2009-10-27 CN CN2009801526261A patent/CN102264371B/zh active Active
- 2009-10-27 MY MYPI2011001828A patent/MY161890A/en unknown
- 2009-10-27 EA EA201170617A patent/EA021927B1/ru not_active IP Right Cessation
- 2009-10-27 US US12/606,390 patent/US20100113475A1/en not_active Abandoned
- 2009-10-27 SG SG2013079579A patent/SG195608A1/en unknown
- 2009-10-27 ES ES09829580.1T patent/ES2539835T3/es active Active
- 2009-10-27 SI SI200931192T patent/SI2421537T1/sl unknown
- 2009-10-27 HR HRP20150531TT patent/HRP20150531T1/hr unknown
2011
- 2011-04-17 IL IL212444A patent/IL212444A/en not_active IP Right Cessation
- 2011-04-18 ZA ZA2011/02892A patent/ZA201102892B/en unknown
- 2011-04-22 MA MA33791A patent/MA32727B1/fr unknown
- 2011-04-26 CL CL2011000933A patent/CL2011000933A1/es unknown
- 2011-04-27 DO DO2011000113A patent/DOP2011000113A/es unknown
- 2011-04-29 US US13/097,271 patent/US20110269774A1/en not_active Abandoned
- 2011-05-11 CO CO11058067A patent/CO6361929A2/es active IP Right Grant
- 2011-05-17 CR CR20110264A patent/CR20110264A/es unknown
2013
- 2013-10-07 US US14/047,688 patent/US9012479B2/en active Active
2015
- 2015-03-30 US US14/672,477 patent/US20150265589A1/en not_active Abandoned
- 2015-05-22 CY CY20151100462T patent/CY1116399T1/el unknown
- 2015-07-03 SM SM201500157T patent/SMT201500157B/xx unknown
- 2015-10-20 US US14/887,763 patent/US9446034B2/en active Active

Also Published As

Publication number	Publication date
PT2421537E (pt)	2015-07-03
KR20110080172A (ko)	2011-07-12
JO3067B1 (ar)	2017-03-15
IL212444A (en)	2015-11-30
EA201170617A1 (ru)	2011-12-30
EP2421537B1 (en)	2015-04-08
RS54045B1 (sr)	2015-10-30
UY32200A (es)	2010-05-31
CA2741760C (en)	2016-02-23
US20150265589A1 (en)	2015-09-24
US9446034B2 (en)	2016-09-20
JP5642689B2 (ja)	2014-12-17
BRPI0920053A2 (pt)	2015-12-15
AU2009320144A1 (en)	2010-06-03
HRP20150531T1 (hr)	2015-06-19
SI2421537T1 (sl)	2015-06-30
PE20110941A1 (es)	2012-02-08
KR101512217B1 (ko)	2015-04-15
EA021927B1 (ru)	2015-09-30
EP2421537A4 (en)	2012-06-13
IL212444A0 (en)	2011-06-30
CL2011000933A1 (es)	2011-10-21
SMT201500157B (it)	2015-09-07
ES2539835T3 (es)	2015-07-06
US20100113475A1 (en)	2010-05-06
AU2009320144B2 (en)	2013-11-21
BRPI0920053B1 (pt)	2019-11-26
AR073993A1 (es)	2010-12-15
EP2421537A1 (en)	2012-02-29
DOP2011000113A (es)	2011-07-15
JP2012506876A (ja)	2012-03-22
PL2421537T3 (pl)	2015-08-31
WO2010062578A1 (en)	2010-06-03
CA2741760A1 (en)	2010-06-03
US20110269774A1 (en)	2011-11-03
CY1116399T1 (el)	2017-02-08
MY161890A (en)	2017-05-15
NZ592477A (en)	2013-01-25
MX2011004369A (es)	2011-05-25
CN102264371B (zh)	2013-10-02
TW201028394A (en)	2010-08-01
ZA201102892B (en)	2012-02-29
TWI454467B (zh)	2014-10-01
HK1161680A1 (en)	2012-08-03
US20160095841A1 (en)	2016-04-07
US9012479B2 (en)	2015-04-21
US20140107131A1 (en)	2014-04-17
SG195608A1 (en)	2013-12-30
US20110207743A1 (en)	2011-08-25
MA32727B1 (fr)	2011-10-02
BRPI0920053B8 (pt)	2021-05-25
CR20110264A (es)	2011-10-04
CN102264371A (zh)	2011-11-30
CO6361929A2 (es)	2012-01-20

Publication	Publication Date	Title
DK2421537T3 (da)	2015-06-22	Pyrazolylaminopyridiner som inhibitorer af FAK
CY2020023I2 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
DK2419429T3 (da)	2014-06-23	Imidazopyraziner som inhibitorer af proteinkinaser
LTPA2017039I1 (lt)	2017-12-11	Pirolopirimidino junginiai, kaip CDK inhibitoriai
DK2421825T3 (da)	2014-02-03	Azetidinyldiamider som monoacylglycerollipase-inhibitorer
DK3208269T3 (da)	2021-10-11	Inhibitorer af c-fms-kinase
DK2315756T3 (da)	2014-10-13	1,2,5-oxadiazoler som inhibitorer af indolamin-2,3-dioxygenase
DK2448938T3 (da)	2014-08-25	Pyrimidinoner som pi3k-inhibitorer
DK1981875T3 (da)	2014-07-14	Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
DK2406253T3 (da)	2013-08-12	Benzofuranylderivater anvendt som glucokinase-inhibitorer
DK2139892T3 (da)	2011-12-12	Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
SMT201600267B (it)	2016-08-31	Inibitori di syk imidazopirazinici
DK2475657T3 (da)	2013-09-23	5-Alkynylthien-2-ylcarboxylsyrer som inhibitorer af flaviviridae-vira
DK3354650T3 (da)	2022-05-30	Forbindelser der er nyttige som inhibitorer af ATR-kinase
DK2389382T3 (da)	2013-07-08	Aminoheterocykliske forbindelser anvendt som pde9-inhibitorer
DK2300465T3 (da)	2019-06-24	Imidazopyridinderivater som hæmmere af receptortyrosinkinaser
DK3354652T3 (da)	2020-05-18	Piperidin-4-yl azetidinderivativer som jak1-inhibitorer
DK2317851T3 (da)	2014-04-14	Anvendelse af 5-fluorcytosin som fungicid
DK2318389T3 (da)	2013-09-30	Pyridazinderivater som SMO-inhibitorer
DK2271642T3 (da)	2014-04-22	Pyridylinhibitorer af hedgehog signalering
DK2262793T3 (da)	2012-10-15	Krystallinske former af nilotinib-hci
DK2242752T3 (da)	2012-11-19	Imidazolyl-biphenylimidazoler som hepatitis C-virus-inhibitorer
DK2086939T3 (da)	2010-10-11	Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK2117523T3 (da)	2014-09-08	Inhibitorer af AKT-aktivitet
DK2178840T3 (da)	2012-03-26	Azabiphenylaminobenzoesyre-derivater som dhodh-hæmmere